Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prochloraz SCHEMBL22242 | 0.99 | AHR (1.00) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL34675 | 0.99 | AHR (1.00) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL11376171 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL11379280 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL11381653 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL9371936 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL12611119 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL11375792 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL10346525 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 | |
| Prochloraz SCHEMBL7128363 | 0.98 | AHR (0.98) | AHRADRB2ADRB1ADRB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109305959-B | Pyrimidinyl tyrosine kinase inhibitors | 比奥根MA公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113549055-A | Pyrimidinyl tyrosine kinase inhibitors | 比奥根MA公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-109169655-B | Mesoporous silica-based drug carrier and preparation method thereof | 国家纳米科学中心 | 2021-01-01 | — | — | CN | disclosed |
| CN-108990973-B | Graphene oxide/chitosan quaternary ammonium salt composite material and preparation method and application thereof | 国家纳米科学中心 | 2020-12-29 | — | — | CN | disclosed |
| CN-109305959-A | Pyrimidine radicals tyrosine kinase inhibitor | 比奥根MA公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-109169655-A | A kind of pharmaceutical carrier and preparation method thereof based on mesoporous silicon oxide | 国家纳米科学中心 | 2019-01-11 | — | — | CN | disclosed |
| CN-108990973-A | Graphene oxide/chitosan quaternary ammonium salt composite material and preparation method and application | 国家纳米科学中心 | 2018-12-14 | — | — | CN | disclosed |
| CN-104540385-B | pyrimidinyl tyrosine kinase inhibitors | 比奥根MA公司 | 2018-06-05 | — | — | CN | disclosed |
| US-20070184514-A1 | METHODS AND COMPOSITIONS FOR DETECTING ACTIVE COMPONENTS USING BIOLUMINESCENT BACTERIA AND THIN-LAYER CHROMATOGRAPHY | WESTERN ALLIANCE BANK | 2007-08-09 | — | — | US | disclosed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-6486165-B2 | TREATING WITH AGONISTS AT KAPPA OPIOID RECEPTORS SUCH AS METHYL-4-(2-GLYCYL-4-(TRIFLUOROMETHYLPHENYL)ACETYL)-3-(R,S)-((1 -PYRROLIDINYL)-METHYL)-1-PIPERAZINECARBOXYLATE | ADOLOR CORPORATION | 2002-11-26 | — | — | US | disclosed |
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6303611-B1 | FOR THERAPY OF HYPERALGESIS | ADOLOR CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1112252-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6057323-A | PIPERAZINE DERIVATIVES | ADOLOR CORPORATION (US) | 2000-05-02 | — | — | US | disclosed |
| WO-2000014065-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103164-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | AHR 1924/4885ADRB2 41/4885ADRB1 48/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | AHR 1125/4885ADRB2 26/4885ADRB1 27/4885 |
| US-20020013296-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, HRH4 | AHR 1924/4885ADRB2 41/4885ADRB1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.